Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01878513 · ClinicalTrials.gov registry record · NA
Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis
A NA study, sponsored by Northwell Health.
- Completed
- Registry status
- NA
- Development phase
- 88
- Enrollment target
NCT01878513 is a NA study that has completed, run by Northwell Health. The registered enrollment target is 88 participants.
The verdict
NCT01878513, a NA study, has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
Study Summary
The aim of the study is to examine whether determining treatment strategies based upon Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome in patients with psychosis. The investigators predict that prospectively testing CYP2D6 genotype and using this information to treat psychotic patients with risperidone will improve clinical outcomes. Specifically, CYP2D6 poor metabolizers who are treated with low dose and slow titration of risperidone will do better than those who are treated with usual dose and titration approach in terms of rates of side effects and clinical improvement.
Interventions
- DRUG risperidone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2009-09-23 |
| Est. Completion | 2018-07-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01878513
The ClinicalTrials.gov registry entry for NCT01878513 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 88 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which risperidone is the first listed.
NCT01878513 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01878513 about?
NCT01878513 is a clinical study titled "Prospective Cytochrome P450 Genotyping and Clinical Outcomes in Patients With Psychosis". The aim of the study is to examine whether determining treatment strategies based upon Cytochrome P450 2D6 (CYP2D6) genotype will improve drug response rates and clinical outcome in patients with psychosis. The investigators predict that prospectively testing CYP2D6 genotype and using this informat...
What is the current status of trial NCT01878513?
This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2009-09-23. Estimated completion is 2018-07-31.
What interventions are being tested in trial NCT01878513?
The interventions under investigation include: risperidone (DRUG).
Who is sponsoring clinical trial NCT01878513?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.